Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Receivables - Accured (2019 - 2025)

Historic Receivables - Accured for Spyre Therapeutics (SYRE) over the last 7 years, with Q3 2025 value amounting to $3.6 million.

  • Spyre Therapeutics' Receivables - Accured rose 11176.47% to $3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.6 million, marking a year-over-year increase of 11176.47%. This contributed to the annual value of $3.4 million for FY2024, which is 27777.78% up from last year.
  • Latest data reveals that Spyre Therapeutics reported Receivables - Accured of $3.6 million as of Q3 2025, which was up 11176.47% from $3.5 million recorded in Q2 2025.
  • Spyre Therapeutics' Receivables - Accured's 5-year high stood at $3.6 million during Q3 2025, with a 5-year trough of $100000.0 in Q3 2021.
  • For the 5-year period, Spyre Therapeutics' Receivables - Accured averaged around $1.3 million, with its median value being $650000.0 (2023).
  • In the last 5 years, Spyre Therapeutics' Receivables - Accured plummeted by 5000.0% in 2021 and then surged by 170000.0% in 2024.
  • Over the past 5 years, Spyre Therapeutics' Receivables - Accured (Quarter) stood at $100000.0 in 2021, then changed by 0.0% to $100000.0 in 2022, then soared by 800.0% to $900000.0 in 2023, then surged by 277.78% to $3.4 million in 2024, then increased by 5.88% to $3.6 million in 2025.
  • Its last three reported values are $3.6 million in Q3 2025, $3.5 million for Q2 2025, and $3.4 million during Q1 2025.